Phase 3 Readout
BIIB: Phase 3 Topline: A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects
June 22, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 22, 2026
- Company
- BIOGEN INC. (BIIB)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout
Phase 3 Topline: A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects
- Company
- BIOGEN INC. (BIIB)
- Indication
- Choroideremia; X-Linked Retinitis Pigmentosa